Thromb Haemost 1990; 64(03): 369-373
DOI: 10.1055/s-0038-1647321
Original Article
Schattauer GmbH Stuttgart

A Specific Thromboxane Receptor Blocking Drug, AH23848, Reduces Platelet Deposition on Vascular Grafts in Man

I F Lane
The Department of Surgery, Charing Cross Hospital, London
,
P Lumley
1  Glaxo Group Research Ltd, Ware, Hertfordshire, U. K.
,
M F Michael
1  Glaxo Group Research Ltd, Ware, Hertfordshire, U. K.
,
A M Peters
1  Glaxo Group Research Ltd, Ware, Hertfordshire, U. K.
,
C N McCollum
The Department of Surgery, Charing Cross Hospital, London
› Author Affiliations
Further Information

Publication History

Received: 23 November 1989

Accepted after revision23 May 1990

Publication Date:
25 July 2018 (online)

Summary

The antithrombotic effect of a specific thromboxane A2 receptor blocking drug, AH23848, on radio-labelled platelet deposition in mature Dacron aorto-bifemoral grafts has been evaluated in patients. Thirty patients were randomly allocated to AH23848 70 mg, aspirin 300 mg plus dipyridamole 75 mg or placebo 8-hourly for 9 days. AH23848 inhibited platelet aggregarion induced by the thromboxane ,A2 mimetic U-46619; no such effect was observed with aspirin plus dipyridamole. 111In-platelet uptake was measured as the thrombogenicity index (TI) which is a measure of the daily rate of accumulation of platelets by the graft. The mean (s.e. mean) value of 0.193 (0.029) on placebo was significantly reduced to 0.115 (0.022) by AH23848 (p <0.05) but only to 0.175 (0.028) by aspirin plus dipyridamole. There was no difference in mean platelet life span between the three treatment groups. The pronounced antithrombotic effect of AH23848 implicates thromboxane ,A2 in the process of platelet deposition in arterial prostheses and demonstrates the considerable promise of thromboxane receptor blocking drugs as antithrombotic therapy.